Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Mercedes Benz invests in Tamie Mbombo’s company
2016-03-24

Description: Tamie Mbombo Tags: Tamie Mbombo

Tamie Mbombo means business: The Founder and CEO of Sollo Inc, the integrated marketing company endorsed recently by Mercedes Benz South Africa.
Photo:  Hannes Pieterse

A new Mercedes Benz 116 CDI Vito Tourer Pro, a financial injection of R85 000, and 12 months of media coverage by Mercedes Benz is what many Small to Medium Enterprises dream of. For Sollo Inc, that dream became a reality recently after the company won the Boost Your Business 2015 national competition.

In 2012, when Tamie Mbombo was an Investment and Management Banking student at the University of the Free State (UFS), he founded an integrated marketing company, and named it Sollo Inc. The company was launched at the IdeaStart Accelerator, a business incubator for UFS student entrepreneurs.

Four years later, on Friday 18 March 2016, Sollo Inc reached new heights when one of the world’s leading automobile manufacturers presented the Founder and CEO of Solo Inc with a Vito sponsorship at the Bloemfontein Campus.

In addition to serving corporates and the public sector, as part of its social enterprise aspect, Sollo Inc offers certain services free of charge to small businesses. “We capacitate start-ups with organisational skills and financial management as well as marketing education,” explained Mbombo.

Sollo Inc was selected as a winner based on the authentic story behind how Mbombo conducts business. “Mercedes Benz has invested quite a huge sum of money in print and digital media placements as platforms to give exposure to the story behind Sollo Inc,” said Adeesha Ramprith, Client Service Manager at Aqua Online,  Mercedes Benz’s digital marketing agency.

The IdeaStart Accelerator office has commended Mbombo as an example of how young entrepreneurs should keep their ears to the ground, and grab opportunities that might propel their businesses forward. “This is a great milestone for his business, mainly because of the challenges he has faced when it comes to mobility,” said Ayanda Makhanya, Student Entrepreneurship officer at IdeaStart Accelerator.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept